Development of a high-sensitivity ELISA detecting IgG, IgA and IgM antibodies to the SARS-CoV-2 spike glycoprotein in serum and saliva

Research output: Contribution to journalArticlepeer-review

Authors

External organisations

  • University of Southampton
  • University of Oxford
  • Nuffield Department of Clinical Medicine
  • University of Birmingham
  • Queen Elizabeth Hospital
  • University Hospital of Wales

Abstract

Detecting antibody responses during and after SARS-CoV-2 infection is essential in determining the seroepidemiology of the virus and the potential role of antibody in disease. Scalable, sensitive and specific serological assays are essential to this process. The detection of antibody in hospitalized patients with severe disease has proven relatively straightforward; detecting responses in subjects with mild disease and asymptomatic infections has proven less reliable. We hypothesized that the suboptimal sensitivity of antibody assays and the compartmentalization of the antibody response may contribute to this effect. We systematically developed an ELISA, optimizing different antigens and amplification steps, in serum and saliva from non-hospitalized SARS-CoV-2-infected subjects. Using trimeric spike glycoprotein, rather than nucleocapsid, enabled detection of responses in individuals with low antibody responses. IgG1 and IgG3 predominate to both antigens, but more anti-spike IgG1 than IgG3 was detectable. All antigens were effective for detecting responses in hospitalized patients. Anti-spike IgG, IgA and IgM antibody responses were readily detectable in saliva from a minority of RT-PCR confirmed, non-hospitalized symptomatic individuals, and these were mostly subjects who had the highest levels of anti-spike serum antibodies. Therefore, detecting antibody responses in both saliva and serum can contribute to determining virus exposure and understanding immune responses after SARS-CoV-2 infection.

Bibliographic note

Funding Information: AFC is grateful for funding from the Medical Research Council, the Global Challenges Research Fund (GCRF) and the Institute for Global Innovation (IGI, Project 3107) of the University of Birmingham. This study was supported by the UK National Institute for Health Research, Birmingham Biomedical Research Centres Funding scheme. The work in Prof. Max Crispin's laboratory was funded by the International AIDS Vaccine Initiative, Bill and Melinda Gates Foundation through the Collaboration for AIDS Vaccine Discovery (OPP1196345/INV‐008813, OPP1084519 and OPP1115782), the Scripps Consortium for HIV Vaccine Development (CHAVD) (NIH: National Institute for Allergy and Infectious Diseases AI144462) and the University of Southampton Coronavirus Response Fund. MJP is funded by the Welsh Clinical Academic Training (WCAT) programme and is a participant in the NIH Graduate Partnership Program. The CoCo study was funded internally by the University of Birmingham and University Hospitals Birmingham NHS Foundation Trust. Publisher Copyright: © 2021 The Authors. Immunology published by John Wiley & Sons Ltd.

Details

Original languageEnglish
JournalImmunology
Early online date1 May 2021
Publication statusE-pub ahead of print - 1 May 2021

Keywords

  • COVID-19, ELISA, SARS-CoV-2, antibodies

ASJC Scopus subject areas